Medpacto to present biomarker results at the American Society for Immuno-oncology SITC 2021

Medpacto to present biomarker results at the American Society for Immuno-oncology SITC 2021 Medpacto (CEO Seong-Jin Kim) announced that it would present additional results derived from biomarker research at the symposium of the Society for Immuno-Oncology (SITC 2021) to be held in the US in November. Medpacto is conducting phase 1b and 2a clinical trials for the combination therapy of ‘Vactosertib’ and ‘Keytruda’, which are being developed in-house for patients with microsatellite stable colorectal cancer. Medpacto is in the process of discovering biomarkers based on the collected clinical..........

원문링크 : Medpacto to present biomarker results at the American Society for Immuno-oncology SITC 2021